Cheiny Shiau, PA
Medical · Los Angeles, CANPI 1477036895
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AbbVie at 38.0% of the total. 2025 is the largest year on record at $38,056, more than ten times the $2,492 reported in 2021. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,330 payments — averaging $64.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- UCB, Inc.$15K
- Galderma Laboratories, L.p.$15K
- Arcutis Biotherapeutics, Inc.$6K
- Sanofi$3K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $13K from 24 others
What the payments were for
- Consulting fees$3,6254%
- Speaking & faculty fees$42,66549%
- Travel & lodging$6,1237%
- Food & beverage$33,51839%
- Education$4731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 423 | $32,803 |
| UCB, Inc. | 152 | $14,547 |
| Galderma Laboratories, L.p. | 54 | $14,511 |
| Arcutis Biotherapeutics, Inc. | 65 | $6,294 |
| Sanofi | 59 | $2,558 |
| E.r. Squibb & Sons, L.L.C. | 94 | $2,248 |
| Novartis | 72 | $1,961 |
| Amgen | 56 | $1,794 |
| Regeneron Healthcare Solutions, Inc. | 43 | $1,570 |
| Lilly USA, LLC | 53 | $1,511 |
| Dermavant Sciences, Inc. | 31 | $1,299 |
| Pfizer | 74 | $1,206 |
| Sun Pharmaceutical Industries Inc. | 20 | $760 |
| Johnson & Johnson | 28 | $714 |
| Incyte Corporation | 22 | $677 |
| LEO Pharma Inc. | 22 | $507 |
| Journey Medical Corporation | 18 | $461 |
| Verrica Pharmaceuticals Inc. | 10 | $241 |
| Sanofi-aventis U.S. LLC | 2 | $198 |
| Mayne Pharma Commercial LLC | 17 | $134 |
| Organon | 4 | $120 |
| Boehringer Ingelheim | 2 | $68 |
| Fresenius Kabi USA, LLC | 2 | $56 |
| Argenx US, Inc. | 1 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Botanix SB Inc | 1 | $25 |
| Dermira, Inc. | 1 | $25 |
| LNHC, Inc | 1 | $20 |
| Almirall LLC | 1 | $17 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,404 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 39 | $781,678 |
| Taltz AutoinjectorIxekizumab | 62 | $447,570 |
| Humira(Cf) PenAdalimumab | 48 | $381,656 |
| Dupixent PenDupilumab | 105 | $379,228 |
| SkyriziRisankizumab-Rzaa | 15 | $303,960 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 30 | $234,050 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 11 | $162,926 |
| SotyktuDeucravacitinib | 15 | $107,160 |
| OtezlaApremilast | 14 | $67,097 |
| OpzeluraRuxolitinib Phosphate | 31 | $61,368 |
| ZoryveRoflumilast | 66 | $56,189 |
| Fluocinonide | 174 | $7,042 |
| Fluorouracil | 36 | $3,172 |
| Tretinoin | 68 | $2,718 |
| Betamethasone Dipropionate | 56 | $2,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSkyrizi | $32,803 | $303,96015 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $2,248 | $107,16015 claims |
| AmgenOtezla | $1,794 | $67,09714 claims |
| Incyte CorporationOpzelura | $677 | $61,36831 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $6,294 | $56,18966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Los Angeles
- Jeffrey BonnaudLos Angeles$314K
- Kenny Davis TrinidadLos Angeles$99K
- Xochitl RentelnLos Angeles$38K
- Charlotte CarlsonLos Angeles$30K
- Dorna YaghoobzadehLos Angeles$18K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.